| that's 14 to a vote on uh approving it |
5.76 |
Jump to 19.74 |
CARDINAL
14
|
| 10 to 4 vote on voting for on |
5.82 |
Jump to 28.38 |
CARDINAL
10
CARDINAL
4
|
| just a second but just to recap what |
3.48 |
Jump to 35.7 |
ORDINAL
second
|
| it is a 120 microgram dose administered |
5.58 |
Jump to 39.18 |
CARDINAL
120
|
| 24 to 36 weeks it protects the baby up |
5.459 |
Jump to 44.76 |
DATE
24 to 36 weeks
|
| to six months that's at least the end |
3.6 |
Jump to 48.6 |
DATE
at least the end
|
| number one that uh later in the third |
5.099 |
Jump to 54.96 |
CARDINAL
number one
ORDINAL
third
|
| protection up to 30 days versus after |
4.921 |
Jump to 62.399 |
DATE
up to 30 days
|
| phase three because of certain safety |
3.9 |
Jump to 76.5 |
CARDINAL
three
|
| noted 5.6 in their vaccine group versus |
6.6 |
Jump to 84 |
CARDINAL
5.6
|
| 4.7 Placebo GlaxoSmithKline noted 6.8 |
5.661 |
Jump to 86.759 |
CARDINAL
4.7
PERSON
Placebo GlaxoSmithKline
CARDINAL
6.8
|
| 4.9 and Placebo so the placebo numbers |
4.659 |
Jump to 92.42 |
CARDINAL
4.9
PERSON
Placebo
|
| similar indications one major difference |
5.58 |
Jump to 97.079 |
CARDINAL
one
|
| GlaxoSmithKline was the first to get the |
4.619 |
Jump to 126.36 |
PERSON
GlaxoSmithKline
ORDINAL
first
|
| 60 and older RSV vaccine out so neck and |
4.859 |
Jump to 128.52 |
CARDINAL
60
ORG
RSV
|
| is the only one on the table right now |
2.58 |
Jump to 133.379 |
|
| forward it'll be the first I will |
5.42 |
Jump to 135.959 |
ORDINAL
first
|